Evaluation of Effectiveness and Safety of Ultimaster Tansei Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study
Latest Information Update: 30 Dec 2024
Price :
$35 *
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease
- Focus Adverse reactions
- Acronyms IRIS Tansei
- 24 Dec 2024 Planned End Date changed from 31 Dec 2028 to 31 Dec 2030.
- 24 Dec 2024 Planned primary completion date changed from 17 Sep 2024 to 31 Dec 2026.
- 05 Feb 2023 Planned End Date changed from 31 Dec 2026 to 31 Dec 2028.